文献速递创伤与烧伤复苏、休克与脓毒症

创伤患者补充纤维蛋白原:应选择纤维蛋白原浓缩物而非冷沉淀吗

Fibrinogen supplementation for the trauma patient: Should you choose fibrinogen concentrate over cryoprecipitate?
PubMed 文献 · J Trauma Acute Care Surg · 2022-07-15
一句话结论回顾性配对队列显示,创伤出血患者用纤维蛋白原浓缩物较冷沉淀减少输血需求并缩短住院和ICU时间,并发症与病死率无显著差异。

该研究基于美国外科医师学会创伤质量改进项目2016—2017年数据,开展为期2年的回顾性队列分析,纳入接受纤维蛋白原浓缩物(FC)或冷沉淀(Cryo)作为复苏辅助的成人创伤患者,排除出血性疾病、慢性肝病及伤前抗凝者,按1:2倾向性评分匹配。匹配后共255例(FC组85例,Cryo组170例),平均年龄41±19岁,男性74%,白人74%,损伤严重度评分中位数26(22-30)。与Cryo组相比,FC组输注红细胞、新鲜冰冻血浆和血小板单位更少,住院和ICU时间更短;两组主要院内并发症和病死率无显著差异。作者结论认为FC与改善结局和减少输血需求相关,但需进一步研究确定创伤复苏中补充纤维蛋白原的最佳方法。

要点

  • 匹配队列255例(FC组85例,Cryo组170例),FC组较Cryo组输注红细胞、新鲜冰冻血浆和血小板单位更少。
  • FC组住院时间和ICU时间均短于Cryo组。
  • 两组主要院内并发症和病死率无显著差异。
  • 证据等级为治疗/护理管理Level III,作者认为需进一步研究确定最佳补充方法。

适用人群与场景

  • 成人创伤患者(≥18岁)接受纤维蛋白原浓缩物或冷沉淀作为复苏辅助。
  • 排除出血性疾病、慢性肝病及伤前使用抗凝药的患者。

研究设计与关键结果

  • 研究类型:基于美国外科医师学会创伤质量改进项目数据库的2年(2016—2017)回顾性队列分析,采用1:2倾向性评分匹配。
  • 匹配队列255例:FC组85例,Cryo组170例;平均年龄41±19岁,男性74%,白人74%,损伤严重度评分中位数26(22-30)。
  • 与Cryo组相比,FC组所需红细胞、新鲜冰冻血浆和血小板单位更少,住院和ICU时间更短。
  • 两组主要院内并发症和病死率无显著差异。

证据类型、等级与局限

  • 证据类型:回顾性队列分析;证据等级:治疗/护理管理Level III。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对创伤出血患者使用纤维蛋白原浓缩物与改善结局和减少输血需求相关,但需进一步研究评估创伤复苏中补充纤维蛋白原的最佳方法。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Trauma-induced coagulopathy is frequently associated with hypofibrinogenemia. Cryoprecipitate (Cryo), and fibrinogen concentrate (FC) are both potential means of fibrinogen supplementation. The aim of this study was to compare the outcomes of traumatic hemorrhagic patients who received fibrinogen supplementation using FC versus Cryo.

METHODS: We performed a 2-year (2016-2017) retrospective cohort analysis of the American College of Surgeons Trauma Quality Improvement Program database. All adult trauma patients (≥18 years) who received FC or Cryo as an adjunct to resuscitation were included. Patients with bleeding disorders, chronic liver disease, and those on preinjury anticoagulants were excluded. Patients were stratified into those who received FC, and those who received Cryo. Propensity score matching (1:2) was performed. Outcome measures were transfusion requirements, major complications, hospital, and intensive care unit lengths of stay, and mortality.

RESULTS: A matched cohort of 255 patients who received fibrinogen supplementation (85 in FC, 170 in Cryo) was analyzed. Overall, the mean age was 41 ± 19 years, 74% were male, 74% were white and median Injury Severity Score was 26 (22-30). Compared with the Cryo group, the FC group required less units of packed red blood cells, fresh frozen plasma, and platelets, and had shorter in-hospital and intensive care unit length of stay. There were no significant differences between the two groups in terms of major in-hospital complications and mortality.

CONCLUSION: Fibrinogen supplementation in the form of FC for the traumatic hemorrhagic patient is associated with improved outcomes and reduced transfusion requirements as compared with Cryo. Further studies are required to evaluate the optimal method of fibrinogen supplementation in the resuscitation of trauma patients.

LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Obaid O, Anand T, Nelson A, et al. Fibrinogen supplementation for the trauma patient: Should you choose fibrinogen concentrate over cryoprecipitate? J Trauma Acute Care Surg. 2022. PMID: 35838235. doi:10.1097/TA.0000000000003728

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。